MYC and acute myeloid leukemia: Meanwhile, the study also found that m6A modification could exert oncogenic effects via elevating the translation level of related mRNAs [e.g., c-MYC, B-cell lymphoma/leukemia-2 (BCL2), phosphatase and tensin homolog deleted on chromosome ten (PTEN) gene, etc.] in AML cells, thus further suggesting that METTL3 can act as an oncogenic factor in myeloid malignancies, which is an important reference value for clinical treatment.